Unity Biotechnology Unveils Mixed Data From Study For Diabetes-Related Blindness, Stock Falls
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 24 2025
0mins
Source: Benzinga
Stock Performance: Unity Biotechnology's stock (UBX) dropped 34.8% to $1.19 following the release of results from its Phase 2b ASPIRE clinical trial for UBX1325, which showed non-inferiority to aflibercept in treating diabetic macular edema.
Study Findings: The trial indicated that UBX1325 led to significant visual acuity improvements over 24 and 36 weeks, particularly benefiting patients with moderate disease severity, while maintaining a favorable safety profile.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy REGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on REGN
Wall Street analysts forecast REGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for REGN is 808.50 USD with a low forecast of 637.00 USD and a high forecast of 1057 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
22 Analyst Rating
16 Buy
6 Hold
0 Sell
Moderate Buy
Current: 749.440
Low
637.00
Averages
808.50
High
1057
Current: 749.440
Low
637.00
Averages
808.50
High
1057
About REGN
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Regeneron Pharmaceuticals Reports Q4 2025 Earnings Highlights
- Revenue Growth: In Q4 2025, Regeneron reported total revenues of $3.9 billion, reflecting a 3% year-over-year increase, primarily driven by double-digit sales growth of key products like DUPIXENT, LIBTAYO, and EYLEA HD, indicating strong performance in the biopharmaceutical sector.
- Product Sales Highlights: Global net sales of DUPIXENT surged by 32%, while EYLEA HD sales in the U.S. skyrocketed by 66%, which not only solidifies Regeneron's leadership in the innovative antibody market but also lays a foundation for future market expansion.
- R&D Investment Plans: The company anticipates R&D spending to range between $5.9 billion and $6.1 billion in 2026, with plans to initiate 18 new Phase III clinical studies targeting approximately 35,000 patients, setting the stage for Regeneron's next wave of potential blockbuster products.
- Shareholder Returns: In 2025, Regeneron returned $3.8 billion to shareholders, primarily through $3.4 billion in share repurchases, demonstrating a balanced strategy between ongoing investments and shareholder returns.
Continue Reading
McDonald Capital Increases Stake in FactSet Research Systems
- Stake Acquisition: McDonald Capital Investors disclosed a purchase of 86,891 shares of FactSet Research Systems during Q4, valued at approximately $24.39 million, indicating strong confidence in the company.
- Value Increase: Following the acquisition, McDonald Capital's position in FactSet rose to $53.90 million, an increase of $25.58 million from the previous quarter, reflecting both share additions and price appreciation.
- Portfolio Diversification: FactSet now represents 3.31% of McDonald Capital's portfolio, alongside other major holdings like Progressive and Regeneron, aligning with a long-term compounding investment strategy.
- Business Resilience: Despite a 45% decline in FactSet's stock price over the past year, the company continues to report organic revenue growth and strong free cash flow, underscoring the durability and sustainability of its business model.
Continue Reading